Adelaide Research & Scholarship: Search

Search

Results 11-20 of 28 (Search time: 0.003 seconds).

Item hits:

Preview	Issue Date	Title	Author(s)
	2011	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial	Kantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
	2010	Practical considerations for monitoring patients with chronic myeloid leukemia	Branford, S.; Hughes, T.
	2003	Molecular monitoring of chronic myeloid leukemia	Hughes, T.; Branford, S.
	2003	Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors	Dewar, A.; Domaschenz, R.; Doherty, K.; Hughes, T.; Lyons, A.
	2003	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia	Hughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
	2010	Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia	Saglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
	2004	Clinical resistance to imatinib: mechanisms and implications	Hochhaus, A.; Hughes, T.
	2009	Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phase	Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A.
	2009	Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?	Branford, S.; Vaz de Melo, J.; Hughes, T.
	2009	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations	Muller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.